Physician profile
Robert T Clark
NPI 1386648087
$4,674.69
in general payments reported to CMS, 2019-2025
23 companies · $278 in 2025
The $278 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $644 · 2020: $357 · 2021: $631 · 2022: $630 · 2023: $2,104 · 2024: $29.09 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,338 · Food and Beverage: $1,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,337.86 |
| Food and Beverage | $1,073.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,802.09 | 2023 | |
| Johnson & Johnson Surgical Vision, INC. | $683.58 | 2019-2023 | Tecnis Iol |
| Alcon Vision LLC | $461.77 | 2019-2025 | Hydrus Microstent, Argos |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $243.33 | 2019-2021 | |
| Allergan, INC. | $226.40 | 2020-2022 | |
| Abbvie INC. | $204.50 | 2022-2024 | Durysta |
| Rxsight INC | $138.89 | 2023 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Novartis Pharmaceuticals Corporation | $124.48 | 2020-2023 | |
| Glaukos Corporation | $123.34 | 2025 | Idosetr |
| Sun Pharmaceutical Industries INC. | $106.31 | 2019-2023 | Cequa |
| Eyevance Pharmaceuticals LLC | $80.76 | 2021-2022 | |
| Shire North American Group INC | $75.99 | 2019 | |
| Lensar, INC. | $62.75 | 2025 | Lensar Laser System |
| Sight Sciences, INC. | $53.68 | 2022 | |
| Kala Pharmaceuticals, INC. | $53.66 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $46.27 | 2021-2023 | |
| Oyster Point Pharma, INC. | $44.53 | 2022-2023 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $42.48 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $34.95 | 2025 | |
| Lkc Technologies, INC. | $17.74 | 2025 | |
| Dompe US, INC. | $17.62 | 2021 | |
| Aerie Pharmaceuticals, INC. | $17.25 | 2019 | |
| Beaver-Visitec International, INC. | $12.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.